TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Down 4.3% – Here’s Why

Shares of TransCode Therapeutics Inc. (NASDAQ:RNAZ) dropped 4.3% during trading on Wednesday . The company traded as low as $7.51 and last traded at $7.52. Approximately 8,604 shares changed hands during trading, an increase of 43% from the average daily volume of 6,003 shares. The stock had previously closed at $7.86.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

TransCode Therapeutics Stock Performance

The firm has a market capitalization of $6.92 million, a price-to-earnings ratio of -0.08 and a beta of 1.39. The business has a fifty day moving average price of $8.99 and a 200 day moving average price of $9.25.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.